STOCK TITAN

[Form 4] CLOVER HEALTH INVESTMENTS, CORP. /DE Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Negative)
Form Type
4

Clover Health Investments, Corp. (CLOV) reported an insider transaction on a Form 4. Officer Jamie L. Reynoso (CEO, Medicare Advantage) had 71,432 shares of Class A Common Stock automatically withheld on 10/15/2025 to cover taxes from RSU vesting, at a transaction price of $2.8 per share (Code F).

Following this tax withholding, the insider beneficially owns 2,971,740 shares, held directly. The RSUs were granted on 10/15/2024; 25% vested on 10/15/2025. The remaining RSUs vest quarterly in equal 6.25% installments through 10/15/2028, subject to continued service.

Clover Health Investments, Corp. (CLOV) ha riportato una transazione interna su un Form 4. L'ufficiale Jamie L. Reynoso (CEO, Medicare Advantage) ha trattenuto automaticamente 71.432 azioni di Class A Common Stock il 15/10/2025 per coprire le tasse derivanti dalla vesting degli RSU, al prezzo di transazione di 2,8 dollari per azione (Codice F).

A seguito di questa trattenuta fiscale, l'interno azioni beneficiari detiene direttamente 2.971.740 azioni. Gli RSU sono stati concessi il 15/10/2024; il 25% è maturato il 15/10/2025. Le RSU rimanenti maturano trimestralmente in rate uguali del 6,25% entro il 15/10/2028, soggette a continuato servizio.

Clover Health Investments, Corp. (CLOV) informó una transacción interna en un Formulario 4. El funcionario Jamie L. Reynoso (CEO, Medicare Advantage) retuvo automáticamente 71.432 acciones de Class A Common Stock el 15/10/2025 para cubrir impuestos derivados del vesting de RSU, a un precio de transacción de 2,8 dólares por acción (Código F).

Después de esta retención de impuestos, el insider posee beneficiosamente 2.971.740 acciones, en forma directa. Los RSU se otorgaron el 15/10/2024; el 25% se consolidó el 15/10/2025. Las RSU restantes vencen trimestralmente en cuotas iguales del 6,25% hasta el 15/10/2028, sujeto a la continuidad del servicio.

Clover Health Investments, Corp. (CLOV) 은 Form 4 에 따른 내부자 거래를 보고했습니다. 임원 Jamie L. Reynoso(CEO, Medicare Advantage) 는 RSU 가속 vesting에서 발생하는 세금을 충당하기 위해 2025년 10월 15일에 Class A 보통주 71,432주를 자동으로 원천공제 받았으며 거래 가격은 주당 2.8달러(코드 F)입니다.

이 세금 원천공제 후 내부자는 직접 2,971,740주를 보유합니다. RSU 는 2024년 10월 15일에 부여되었고 2025년 10월 15일에 25%가 vest 되었습니다. 남은 RSU 는 2028년 10월 15일까지 매 분기 6.25%의 동일한 분할로 vesting되며, 계속 근무 조건에 따릅니다.

Clover Health Investments, Corp. (CLOV) a annoncé une transaction interne sur un formulaire 4. L'officier Jamie L. Reynoso (CEO, Medicare Advantage) a retenu automatiquement 71 432 actions de Class A Common Stock le 15/10/2025 pour couvrir les impôts liés au vesting des RSU, au prix de transaction de 2,8 dollars par action (Code F).

Après cette retenue fiscale, l'actionnaire bénéficiaire détient directement 2 971 740 actions. Les RSU ont été accordées le 15/10/2024 ; 25% se sont vestés le 15/10/2025. Le solde des RSU vesting trimestriellement par tranches égales de 6,25% jusqu'au 15/10/2028, sous réserve de la poursuite du service.

Clover Health Investments, Corp. (CLOV) meldete eine Insider-Transaktion im Rahmen eines Formulars 4. Beamter Jamie L. Reynoso (CEO, Medicare Advantage) behielt am 15.10.2025 automatisch 71.432 Aktien der Class A Common Stock ein, um Steuern aus dem RSU-Vesting zu decken, zum Transaktionspreis von 2,8 USD pro Aktie (Code F).

Nach dieser Steuerabführung besitzt der Insider direkt 2.971.740 Aktien. Die RSUs wurden am 15.10.2024 gewährt; 25% sind am 15.10.2025 vestet. Die verbleibenden RSUs vesten vierteljährlich in gleichen 6,25%-Raten bis zum 15.10.2028, vorbehaltlich fortgesetzter Dienstzeit.

أعلنت Clover Health Investments, Corp. (CLOV) عن صفقة داخلية في استمارة 4. أفاد الموظف Jamie L. Reynoso (المدير التنفيذي، Medicare Advantage) بأنه تم حجز 71,432 سهماً من Class A Common Stock تلقائياً في 15/10/2025 لتغطية الضرائب الناتجة عن vesting لـ RSU، بسعر صفقة 2.8 دولار للسهم (رمز F).

بعد هذا الحجز الضريبي، يمتلك الداخل فعلياً 2,971,740 سهماً مباشرة. تم منح RSU في 15/10/2024؛ 25% منها وصلت إلى vest في 15/10/2025. تتغير RSU المتبقية في فترات فصلية بمقدار 6.25% حتى 15/10/2028، رهناً باستمرار الخدمة.

Clover Health Investments, Corp. (CLOV) 在 Form 4 上报告了一笔内幕交易。 高管 Jamie L. Reynoso(CEO,Medicare Advantage)于 2025/10/15 自动预扣了 71,432 股 A 类普通股以覆盖因 RSU 归属产生的税款,交易价格为每股 2.8 美元(代码 F)。

扣税后,该内幕人士直接持有 2,971,740 股。RSU 授予日为 2024/10/15;25% 于 2025/10/15 完成归属。剩余的 RSU 将在 2028/10/15 前以每季度等额的 6.25% 分期归属,前提是持续任职。

Positive
  • None.
Negative
  • None.

Clover Health Investments, Corp. (CLOV) ha riportato una transazione interna su un Form 4. L'ufficiale Jamie L. Reynoso (CEO, Medicare Advantage) ha trattenuto automaticamente 71.432 azioni di Class A Common Stock il 15/10/2025 per coprire le tasse derivanti dalla vesting degli RSU, al prezzo di transazione di 2,8 dollari per azione (Codice F).

A seguito di questa trattenuta fiscale, l'interno azioni beneficiari detiene direttamente 2.971.740 azioni. Gli RSU sono stati concessi il 15/10/2024; il 25% è maturato il 15/10/2025. Le RSU rimanenti maturano trimestralmente in rate uguali del 6,25% entro il 15/10/2028, soggette a continuato servizio.

Clover Health Investments, Corp. (CLOV) informó una transacción interna en un Formulario 4. El funcionario Jamie L. Reynoso (CEO, Medicare Advantage) retuvo automáticamente 71.432 acciones de Class A Common Stock el 15/10/2025 para cubrir impuestos derivados del vesting de RSU, a un precio de transacción de 2,8 dólares por acción (Código F).

Después de esta retención de impuestos, el insider posee beneficiosamente 2.971.740 acciones, en forma directa. Los RSU se otorgaron el 15/10/2024; el 25% se consolidó el 15/10/2025. Las RSU restantes vencen trimestralmente en cuotas iguales del 6,25% hasta el 15/10/2028, sujeto a la continuidad del servicio.

Clover Health Investments, Corp. (CLOV) 은 Form 4 에 따른 내부자 거래를 보고했습니다. 임원 Jamie L. Reynoso(CEO, Medicare Advantage) 는 RSU 가속 vesting에서 발생하는 세금을 충당하기 위해 2025년 10월 15일에 Class A 보통주 71,432주를 자동으로 원천공제 받았으며 거래 가격은 주당 2.8달러(코드 F)입니다.

이 세금 원천공제 후 내부자는 직접 2,971,740주를 보유합니다. RSU 는 2024년 10월 15일에 부여되었고 2025년 10월 15일에 25%가 vest 되었습니다. 남은 RSU 는 2028년 10월 15일까지 매 분기 6.25%의 동일한 분할로 vesting되며, 계속 근무 조건에 따릅니다.

Clover Health Investments, Corp. (CLOV) a annoncé une transaction interne sur un formulaire 4. L'officier Jamie L. Reynoso (CEO, Medicare Advantage) a retenu automatiquement 71 432 actions de Class A Common Stock le 15/10/2025 pour couvrir les impôts liés au vesting des RSU, au prix de transaction de 2,8 dollars par action (Code F).

Après cette retenue fiscale, l'actionnaire bénéficiaire détient directement 2 971 740 actions. Les RSU ont été accordées le 15/10/2024 ; 25% se sont vestés le 15/10/2025. Le solde des RSU vesting trimestriellement par tranches égales de 6,25% jusqu'au 15/10/2028, sous réserve de la poursuite du service.

Clover Health Investments, Corp. (CLOV) meldete eine Insider-Transaktion im Rahmen eines Formulars 4. Beamter Jamie L. Reynoso (CEO, Medicare Advantage) behielt am 15.10.2025 automatisch 71.432 Aktien der Class A Common Stock ein, um Steuern aus dem RSU-Vesting zu decken, zum Transaktionspreis von 2,8 USD pro Aktie (Code F).

Nach dieser Steuerabführung besitzt der Insider direkt 2.971.740 Aktien. Die RSUs wurden am 15.10.2024 gewährt; 25% sind am 15.10.2025 vestet. Die verbleibenden RSUs vesten vierteljährlich in gleichen 6,25%-Raten bis zum 15.10.2028, vorbehaltlich fortgesetzter Dienstzeit.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Reynoso Jamie L.

(Last) (First) (Middle)
C/O CLOVER HEALTH INVESTMENTS, CORP.
NOT APPLICABLE

(Street)
WILMINGTON DE 19801

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
CLOVER HEALTH INVESTMENTS, CORP. /DE [ CLOV ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
CEO, Medicare Advantage
3. Date of Earliest Transaction (Month/Day/Year)
10/15/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Class A Common Stock 10/15/2025 F 71,432(1) D $2.8 2,971,740 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents shares of Class A Common Stock that were automatically withheld to cover tax obligations on October 15, 2025, due to the vesting of 25% of the original number of restricted stock units (RSUs) granted to the Reporting Person on October 15, 2024, and timely reported on a Form 4 filed on October 17, 2024. The remaining RSUs vest quarterly in equal installments of 6.25%, with the final vesting date occurring on October 15, 2028, subject to the continued service of the Reporting Person on each such vesting date.
Remarks:
/s/Peter J. Rivas as attorney-in-fact for Jamie L. Reynoso 10/17/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did CLOV disclose in this Form 4?

An officer had 71,432 Class A shares withheld on 10/15/2025 to cover taxes from RSU vesting at $2.8 per share (Code F).

Who is the reporting person in CLOV's Form 4?

The reporting person is Jamie L. Reynoso, an officer titled CEO, Medicare Advantage.

How many CLOV shares does the insider own after the transaction?

Beneficial ownership after the transaction is 2,971,740 shares, held directly.

What triggered the share withholding for CLOV?

The withholding covered tax obligations arising from RSU vesting on 10/15/2025.

What is the vesting schedule for the CLOV RSUs?

25% vested on 10/15/2025; the remainder vests quarterly in 6.25% installments through 10/15/2028, subject to continued service.

Was this an open-market sale of CLOV shares?

No. It was a tax withholding (Transaction Code F) related to RSU vesting.

Does the filing mention a trading plan under Rule 10b5-1?

The filing includes standard instructions, but the disclosed transaction is a withholding for taxes tied to RSU vesting.
Clover Health Investments Corp

NASDAQ:CLOV

CLOV Rankings

CLOV Latest News

CLOV Latest SEC Filings

CLOV Stock Data

1.38B
403.98M
3.88%
35.27%
9.43%
Healthcare Plans
Hospital & Medical Service Plans
Link
United States
JERSEY CITY